Holen Sie sich die Stockscreener-App
1.56
3.11%
-0.05
Handel nachbörslich:
1.56
Schlusskurs vom Vortag:
$1.61
Offen:
$1.62
24-Stunden-Volumen:
1.69M
Relative Volume:
1.13
Marktkapitalisierung:
$107.18M
Einnahmen:
$832.00K
Nettoeinkommen (Verlust:
$-135.12M
KGV:
-0.2562
EPS:
-6.09
Netto-Cashflow:
$-124.69M
1W Leistung:
-7.69%
1M Leistung:
-28.44%
6M Leistung:
+7.59%
1J Leistung:
-25.36%
1-Tages-Spanne:
$1.545
$1.67
1-Wochen-Bereich:
$1.49
$1.72
52-Wochen-Spanne:
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Vergleichen Sie INO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.56 | 110.61M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Will Inovio Pharmaceuticals Inc. (GBM) stock announce special dividend2025 Investor Takeaways & Low Risk Growth Stock Ideas - ulpravda.ru
Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Why retail investors pile into Inovio Pharmaceuticals Inc. stockJuly 2025 Decliners & Real-Time Buy Zone Alerts - ulpravda.ru
Retail Trends: Will Inovio Pharmaceuticals Inc. (GBM) stock announce special dividendMarket Performance Recap & Daily Price Action Insights - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc.INO - PR Newswire
Looking Into Inovio Pharmaceuticals Inc's Recent Short Interest - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio ... - Bluefield Daily Telegraph
Upcoming Events - FinancialContent
Inovio Pharmaceuticals Inc Stock Analysis and ForecastDividend Stability Analysis & Small Budget Capital Growth - earlytimes.in
Ksolves India Limited Bounces Off Moving Average SupportStock Correlation Metrics & Superior Return Stocks - earlytimes.in
U.S., U.K. Strike Drug Pricing Deal Aimed at Ending Transatlantic Imbalance - MyChesCo
INOVIO Reports Inducement Grant Under Inducement Plan - Eastern Progress
RSI Check: Will Inovio Pharmaceuticals Inc GBM stock announce special dividendEarnings Recap Summary & Free Verified High Yield Trade Plans - moha.gov.vn
FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy - MyChesCo
Inovio respiratory DNA drug candidate shows promise in early trial - MSN
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Inovio drops as respiratory papillomatosis asset denied accelerated review - MSN
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Jefferies reiterates Hold on Inovio stock amid FDA review uncertainty By Investing.com - Investing.com Canada
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - FinancialContent
Inovio stock plummets 25% after FDA denies accelerated review for lead drug candidate - The Business Journals
INOVIO’s DNA therapy for rare throat disease gets FDA review - Indian Pharma Post
Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107 - Investing.com Canada
Boston Herald - FinancialContent
FDA accepts Inovio’s BLA for INO-3107 review - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
FDA setback gives Inovio a headache - The Pharma Letter
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why Is Inovio Pharma Stock Sinking Monday?Inovio Pharmaceuticals (NASDAQ:INO) - Benzinga
Inovio (INO) Shares Plummet 21% After FDA Review Update - GuruFocus
Inovio stock tumbles after FDA questions accelerated approval path By Investing.com - Investing.com Australia
Inovio stock tumbles after FDA questions accelerated approval path - Investing.com India
Inovio Pharmaceuticals Inc: Not Currently Pla - 富途牛牛
EBIT per share of Inovio Pharmaceuticals, Inc. – BIVA:INO - TradingView — Track All Markets
INOVIO (INO) Seeks Accelerated Approval for INO-3107 from FDA - GuruFocus
INOVIO Pharmaceuticals, Inc. Announces FDA Acceptance of BLA for INO-3107 - TradingView — Track All Markets
FDA accepts INOVIO’s BLA for RRP treatment, sets October 2026 target date - Investing.com UK
Rare throat disease may get a new non-surgical treatment option - Stock Titan
INOVIO Issues Equity Award to New Hire as It Rebuilds for Its Next Act - MyChesCo
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INO (Inovio Pharmaceuticals) EV-to-OCF : -1.30 (As of Dec. 22, 2025) - GuruFocus
Sentiment Review: Is AMODW stock attractive for long term wealth buildingGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Published on: 2025-12-22 07:17:12 - moha.gov.vn
INOVIO Advances Toward First Commercial Product as BLA Filing Caps Pivotal Quarter - MSN
Published on: 2025-12-21 00:43:45 - Улправда
Why analysts remain bullish on Inovio Pharmaceuticals Inc. stockIPO Watch & High Return Trade Guides - Улправда
How buyback programs support Inovio Pharmaceuticals Inc. (GBM) stockBond Market & Community Consensus Stock Picks - Улправда
Published on: 2025-12-19 20:43:13 - Улправда
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):